Genmab A/S (NASDAQ:GMAB) Price Target Raised to $42.00 at Guggenheim

Genmab A/S (NASDAQ:GMAB) had its price objective increased by Guggenheim from $40.00 to $42.00 in a research report sent to investors on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

GMAB has been the topic of several other reports. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective on the stock. New Street Research set a $43.00 target price on Genmab A/S in a research note on Wednesday, July 22nd. Finally, HC Wainwright boosted their target price on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $39.50.

Genmab A/S Stock Performance

GMAB stock opened at $31.25 on Friday. The stock has a 50-day moving average price of $27.31 and a 200-day moving average price of $28.01. Genmab A/S has a 1-year low of $21.00 and a 1-year high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The firm has a market cap of $19.49 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.87 and a beta of 0.83.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 6th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.37 by $0.12. Genmab A/S had a return on equity of 15.02% and a net margin of 19.08%.The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.11 billion. As a group, equities research analysts expect that Genmab A/S will post 1.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC raised its holdings in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Genmab A/S during the 1st quarter valued at about $34,000. NewEdge Advisors LLC increased its holdings in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its holdings in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
• Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
• Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
• Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.